RxDoctor Payments Data

Emily Cottrell, MD

Child & Adolescent Psychiatry · Pittsburgh, PANPI 1033538012

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 42.3% of the total. Reporting peaked in 2022 at $523 and has fallen 66.8% since, to $174 in 2024.

$1,225in general payments, 2019–2025

Across 58 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$518
  • Novo Nordisk$123
  • GSK$93
  • Lilly USA, LLC$75
  • AstraZeneca$67
  • Abbott$67
  • plus $282 from 10 others

What the payments were for

  • Food & beverage$1,225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,225 in reported general payments places this provider in the 70th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

See all child & adolescent psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,066
Medicare patients
32
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant14$5,828
Aripiprazole47$1,314
Sertraline Hcl92$1,265
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine18$1,100
Buspirone Hcl60$1,010
Divalproex Sodium12$908
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine18$687
Divalproex Sodium ErDivalproex Sodium12$620
Clonazepam103$518
Venlafaxine Hcl ErVenlafaxine Hcl28$476
Duloxetine Hcl13$420
Fluoxetine Hcl26$417
Quetiapine Fumarate22$400
Mirtazapine18$385
Bupropion XlBupropion Hcl22$359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$17$5,82814 claims
Lilly USA, LLCOlanzapine$75$30325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.

Other child & adolescent psychiatry in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →